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ABSTRACT
In vitro-in vivo extrapolation of drug metabolism data obtained in
enriched preparations of subcellular fractions rely on robust esti-
mates of physiologically relevant scaling factors for the prediction of
clearance in vivo. The purpose of the current study was to measure
the microsomal and cytosolic protein per gram of kidney (MPPGK
and CPPGK) in dog and human kidney cortex using appropriate
protein recovery marker and evaluate functional activity of human
cortex microsomes. Cytochrome P450 (CYP) content and glucose-
6-phosphatase (G6Pase) activity were used as microsomal protein
markers, whereas glutathione-S-transferase activitywas a cytosolic
marker. Functional activity of human microsomal samples was
assessed bymeasuringmycophenolic acid glucuronidation.MPPGK
was 33.9 and 44.0 mg/g in dog kidney cortex, and 41.1 and 63.6 mg/g
in dog liver (n = 17), using P450 content and G6Pase activity,
respectively. No trends were noted between kidney, liver, and
intestinal scalars from the same animals. Species differences were
evident, as human MPPGK and CPPGK were 26.2 and 53.3 mg/g in
kidney cortex (n = 38), respectively. MPPGK was 2-fold greater than
the commonly used in vitro-in vivo extrapolation scalar; this
difference was attributed mainly to tissue source (mixed kidney
regions versus cortex). Robust human MPPGK and CPPGK scalars
were measured for the first time. The work emphasized the impor-
tance of regional differences (cortex versus whole kidney–specific
MPPGK, tissue weight, and blood flow) and a need to account for
these to improve assessment of renal metabolic clearance and its
extrapolation to in vivo.
Introduction
In vitro drug metabolism data obtained in enriched subcellular
fractions such as microsomes or cytosol are commonly scaled using
in vitro-in vivo extrapolation (IVIVE) to predict clearance in vivo
(Houston and Galetin, 2008; Gertz et al., 2010; Nishimuta et al., 2014).
This approach relies on robust estimates of physiologically relevant
scaling factors, including the protein content of the subcellular fraction
in the tissue of interest. Although liver scaling factors have been well
characterized [e.g., microsomal (MPPGL) and cytosolic (CPPGL)
protein per gram of liver] for human and several preclinical species
(Houston, 1994; Barter et al., 2007; Smith et al., 2008; Cubitt et al.,
2011), fewer data have been reported for extrahepatic tissues, such as
the kidney (Gill et al., 2012; Scotcher et al., 2016a,b). Notably, data
are completely lacking for microsomal (MPPGK) and cytosolic
(CPPGK) protein per gram of kidney in preclinical species. Although
several studies have reported microsomal protein yields for rat kidney,
with some also reporting the corresponding data for liver, none of
these reports stated clearly whether the protein recovery was estimated
and accounted for (Jakobsson, 1974; Litterst et al., 1975; Sausen and
Elfarra, 1990; Orellana et al., 2002). In addition, no data exist
for CPPGK in humans, and an estimate of cytosolic protein content of
liver is currently used as a surrogate for IVIVE (Säll et al., 2012;
Nishimuta et al., 2014).
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The MPPGK values for humans range from 5.3 to 32.0 mg/g of
kidney (data based on four literature reports, 23 donors, and different
kidney regions), with weighted (by donor number) mean of 13.6 mg/g of
kidney. Several differences in the designs of these studies are evident,
for example, selection of microsomal protein marker and the region of
kidney used (cortex, medulla, or mixed). It is therefore challenging to
distinguish the contribution of true biologic variability and specific
interstudy differences from the reported MPPGK values and to establish
the most appropriate value to apply as a scaling factor, as summarized in
Fig. 1. A value of 12.8 mg/g of kidney (based on five donors) is the most
commonly used scalar for IVIVE of renal drug metabolism data
(Scotcher et al., 2016a, b). The region of kidney used to obtain this
commonly used scalar is unclear (Al-Jahdari et al., 2006). More recently,
MPPGK data for mixed kidney have been reported (i.e., cortex and
medulla) (Knights et al., 2016). Combining the data from these two
studies resulted in a weighted mean MPPGK of 11.1 mg/g of kidney.
Kidney samples from mixed regions are also used for preparation of
commercially available kidney microsomes (M. Farooq, XenoTech Ltd,
Kansas City, KS). Use of mixed kidney microsomes for IVIVE of renal
drug metabolism is supported by a recent study indicating that differ-
ences in uridine 59-diphospho-glucuronosyltransferase (UGT) activity
between microsomes prepared from the cortex or medulla are reduced
when data are normalized for UGT protein abundance (Knights et al.,
2016). This approach does not take into consideration other differences
between the cortex and medulla, such as content of endoplasmic
reticulum, tissue weight, and blood flows. More specifically, the cortex
represents approximately 68% of kidney weight but receives about 80%
of renal blood flow (Lerman et al., 1996; Vallée et al., 2000). Therefore,
application of in vitro data obtained from mixed kidney microsomes in
the well-stirred kidney model (often applied) may result in inaccurate
IVIVE of renal metabolic clearance (CLR,met). This may be especially
pertinent if data are generated to inform parameters of more mechanistic
kidney physiologically based models that account for regional differ-
ences. Improved confidence in the IVIVE of metabolism by the kidney
will increase the accuracy of predicting overall metabolic clearance,
despite its generally smaller role compared with hepatic metabolism.
Measurement of microsomal or cytosolic protein contents requires the
use of markers of the subcellular fraction of interest. Such markers are
used in a quantitative manner to correct for any protein losses during
centrifugation. Cytochrome P450 (CYP) content is frequently used as a
marker for liver microsomal protein (Barter et al., 2008) but may not be
suitable for the kidney as a result of the lower CYP content in this organ
(Litterst et al., 1975; Song et al., 2015); therefore, alternative markers,
such as glucose-6-phosphatase (G6Pase) and NADPH cytochrome c
reductase activity are preferred (Scotcher et al., 2016b). The activities of
glutathione-S-transferase (GST) and alcohol dehydrogenase have been
reported in the literature for estimation of the cytosolic protein content of
human liver (Cubitt et al., 2011); however, a more thorough assessment
of the suitability of these enzymes as cytosolic protein markers for
kidney is currently lacking.
The aim of this study was to characterize the microsomal and
cytosolic protein content, as well as the functional activity, of kidney
cortex samples from dogs and humans. CYP content and G6Pase activity
were assessed as markers to measure microsomal protein recovery in dog
kidney cortex and liver. In addition, the use of fresh and frozen tissue to
prepare dog kidney cortex homogenates and microsomes and the impact
on subsequent CYP content measurements and MPPGK estimates were
assessed. Microsomal protein recovery in dog liver, kidney cortex, and
intestine was compared using samples from the same animal donors.
After method optimization in dogs, MPPGK and CPPGK were
characterized for 38 human kidney cortex samples using G6Pase and
GST activity as recovery markers, respectively. Impact of age and
Fig. 1. Comparison of kidney regions used to prepare HKMs for in vitro assays and different scaling factors currently used for extrapolation. Matrix-scalar combinations that
have been used in the literature are annotated as being appropriate (green U), inappropriate (red x) or ambiguous/ debatable (blue?). Typically, scaled intrinsic clearance
(CLint) data are subsequently used as input into static or physiologically based kidney models for prediction of in vivo renal metabolic clearance (CLR,met). The assumptions
of a particular kidney model (e.g., well-stirred or with regional/ cellular differences) will dictate the most appropriate matrix and scalar to use for in vitro metabolic data.
Similarly, the availability of tissue for in vitro experiments (e.g., mixed kidney or cortex only) may limit the scaling factor and affect the selection of a kidney model. Adapted
from Fig. 1 in Scotcher et al. (2016a) and references therein, licensed under CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/).
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gender as covariates of MPPGK was investigated for 20 donors for
which data were available. For the same subset, selected UGT
polymorphisms and functional activity of prepared human kidney
cortex microsomes were characterized using mycophenolic acid
glucuronidation substrate depletion assay as activity marker. The
mycophenolic acid unbound intrinsic clearance by glucuronidation
obtained in human kidney cortex microsomes (CLint,u,UGT,HKM) was
scaled by both historical MPPGK for the whole kidney and the newly
acquired MPPGK data for the kidney cortex to assess the impact of
revised scaling factors on predicted renal metabolic clearance.
Materials and Methods
Isolation of Microsomal Protein from Dog Kidney Cortex
Reagents. Chemicals were purchased from Sigma-Aldrich (Gillingham,
Dorset, UK) unless otherwise specified. Homogenization buffer was phosphate-
buffered saline (PBS) with 0.5 mM EDTA, 5 mM histidine, and 0.25 M sucrose,
pH 7.4. Storage buffer was 100 mM Trizma with 0.5 mM EDTA in deionized
water, pH 7.4. CYP assay buffer was 25mM potassium phosphate buffer, pH 7.4,
with 1.5% w/v potassium chloride and 30% v/v glycerol (Fisher Scientific,
Loughborough, UK). G6Pase assay buffer was 100 mM BIS-TRIS, pH 6.5.
Taussky-Shorr color reagent (Taussky and Shorr, 1953) was 0.18 M ferrous
sulfate heptahydrate, 1% w/v ammonium molybdate in 0.5 M sulfuric acid.
Sample Collection and Perfusion. Kidneys and livers from 17 beagle dogs
(4 males, 13 females) were obtained from necropsy at AstraZeneca (Alderley
Park, Macclesfield, UK) according to institutional guidelines in compliance with
national and regional legislation. The age andweights of the dogs ranged from 3.8
to 10.3 years and 19.7 to 20.5 kg, respectively. Liver weights were 315–709 g;
kidney weights were 47–89 g. Livers were transferred to the laboratory in PBS on
ice; kidneys were transferred in PBS containing 9 U/ml of heparin on ice. Kidneys
were perfused with PBS containing 9 U/ml of heparin at 37C at 8 ml/min for
15 min through the renal artery. All subsequent processes were performed on ice
unless specified. Kidneys were cut in half and decapsulated, and each kidney half
was blotted to remove excess liquid and weighed. Kidney halves from one kidney
were frozen at 280C, and the other kidney was used to prepare homogenate.
Pieces of liver (;10–20 g) were washed in PBS, weighed, and frozen at280C.
Dog Homogenate and Microsome Preparation. Homogenization and
centrifugation methods used for preparation of kidney microsomes vary but
generally follow the same core strategy that involves an initial centrifugation of
homogenate at around 9000–12,000 g to remove cellular debris and larger
organelles, followed by ultra-centrifugation of the resulting supernatant at
100,000–110,000 g to obtain the microsomal protein pellet (Supplemental Fig.
S1). The method applied in the current study, which was consistent with this core
strategy, was based on the inhouse method developed for the intestine, with
modifications to optimize homogenization of kidney (Hatley et al., 2017).
Frozen dog tissue samples, stored at 280C, were rapidly thawed at 37C,
washed in PBS, blotted, andweighed. Kidney cortex (2.0–5.0 g) and liver (3.4–4.3 g)
weremincedwith scissors and homogenizedwith 4 to 5ml/gmince of homogenization
buffer. Homogenization was initially with a rotor-stator homogenizer (Omni
International, Kennesaw, GA) with a 10mm 95-mm probe. Bursts of 20 s with
30 s rest on ice were used until no intact pieces of tissue mince were apparent on
visual assessment. The number of bursts for each sample depended on the
starting weight of the minced tissue but required no more than eight bursts for
kidney cortex and four bursts for liver. Samples were further homogenized using
a VibraCell ultrasonic processor (Sonics & Materials, Inc., Newtown, CT) for two
bursts of 10 s, separated with a 30 s resting period on ice to prevent excessive heat
buildup. Homogenate was filtered through 170-mm nylon mesh (Plastok Associates,
Birkenhead, Merseyside, UK). Homogenate volumes were measured, and aliquots
were stored on ice for analysis. Liver and kidney cortex homogenateswere centrifuged
at 9000g at 4C for 15 min using an Optima LE-80K ultracentrifuge with a type
50.2Ti rotor (Beckman Coulter UK Ltd., High Wycombe, Buckinghamshire, UK).
Supernatants were further centrifuged at 105,000g at 4C for 70 min. Aliquots of the
cytosol were retained. The microsomal pellet was resuspended in storage buffer using
a handheld Potter-Elvehjem homogenizer. Samples were stored at 280C.
Microsomal Protein Markers in Dog Samples. Frozen samples were
thawed rapidly at room temperature, and kept on ice until used (Pearce et al.,
1996). Protein in homogenate, microsomes, and cytosol was determined using a
microbicinchoninic acid protein assay kit (Pierce Biotechnology no. 23227;
Pierce Biotechnology, Waltham, MA) according to the manufacturer’s instruc-
tions. Absorbance (562 nm) was measured with a Tecan Safire microplate reader
with XFluor4 software (Reading, Berkshire, UK).
The CYP content of homogenate and microsomal samples was measured
according to the dithionite difference spectroscopy method of Matsubara et al.
(1976). Samples were diluted to 2 mg/ml in CYP assay buffer and bubbled (about
one bubble/s) for 1 minwith carbonmonoxide. Then 1 ml of diluted samples were
dispensed into each of two semi-microcuvettes (VWR, Radnor, PA), and baseline
absorbance spectrum was measured (400–600 nm) using a UV-2401-PC dual-
beam spectrophotometer with UVPC software (Shimadzu, Milton Keynes,
Buckinghamshire, UK), and 10 ml of freshly prepared sodium dithionite
(200 mg/ml in CYP assay buffer) was added to the sample cuvette. The sample
cuvette was inverted 4 times, left to stand for 4 min, and then the absorbance
spectrum measured. CYP content (nmol/mg protein) was calculated using a
molar extinction coefficient (A450–490) of 0.104 (Matsubara et al., 1976).
Interassay variability of CYP content measurements was assessed by repeat
measurements in four batches of homogenates and microsomes from three dogs
(i.e., two batches prepared from the same animal).
Various endogenous contaminants, such as methemoglobin, cytochrome b5,
and cytochrome oxidase, can potentially interfere with CYP content measure-
ments in microsomal samples (Estabrook andWerringloer, 1978; Johannesen and
DePierre, 1978; Burke and Orrenius, 1979). Furthermore, during preliminary
experiments, broad absorbance peaks were observed at approximately 426 and
430 nm in homogenate and microsomes, respectively, which may have interfered
with the A450 measurements and therefore affected CYP content measurement
and MPPGK estimates. It was previously reported that this interference can be
limited by chemically reducing the contaminants during the CYP content assay
(Estabrook and Werringloer, 1978; Burke and Orrenius, 1979). In the current
study, inclusion of 0.25 mM sodium ascorbate and 2.5mMphenazine ethosulfate,
reported to reduce methemoglobin (Burke and Orrenius, 1979), did not cause
substantial change in the dithionite difference spectra for dog kidney cortex
microsomes, although a small shift in the 426-nm peak to 430 nmwas noted (data
not shown). Inclusion of NADH and sodium succinate, which are reported to
reduce cytochrome b5 and cytochrome oxidase (Estabrook and Werringloer,
1978; Burke and Orrenius, 1979), in the CYP content assay buffer caused a
change in the spectra of homogenate (;400–420 nm) and microsomes (;400–
435 nm) (Supplemental Fig. S2). As no major change in baseline or peak at
450 nm was observed, neither the CYP measurements in homogenate and
microsome samples nor the estimates of MPPGK were affected. Therefore, the
sodium dithionite difference spectra assay as reported in the literature (Matsubara
et al., 1976), that is, without modification of buffer constituents, was considered
sufficient for estimation of MPPGK in dogs.
The G6Pase activity was measured in duplicate using a spectrophotometric
method (Nordlie and Arion, 1966). Homogenate and microsomal protein and
glucose-6-phosphate were preincubated separately inG6Pase assay buffer at 37C
for 10 min. Homogenate and microsomes (0.25 mg/ml) were added to the G6P
(1 mM) to initiate the reaction, and an aliquot was immediately quenched (3:1) in
20% trichloroacetic acid on ice (t = 0 min). Additional aliquots were quenched at
5, 15, 30, and 60 min. After centrifugation at 4000 rpm for 10 min, samples and
phosphorous standards were added in 1:1 ratio to Taussky-Shorr color reagent.
Absorbance (660 nm) was measured with a Tecan Safire plate reader with
XFluor4 software. Results were processed with Microsoft Excel. G6Pase activity
was expressed as nanomolars of inorganic phosphate (Pi) formed per min/mg
protein based on the initial linear rate of Pi formation. Interassay variability for
G6Pase activity was assessed by remeasurement of a single set of samples
prepared from the kidneys of three different dogs in three separate assays.
Isolation of Microsomal and Cytosolic Protein from Human Kidney Cortex
Reagents. XenoTech mixed-gender pooled (13 donors) human whole/mixed
kidney microsomes (lot. 1410120; 4-methylumbelliferone glucuronidation activ-
ity of 105 nmol per min/mg of protein) were obtained from Tebu-bio (Peter-
borough, Cambs, UK). Chemicals were purchased from Sigma-Aldrich
(Gillingham, Dorset, UK) unless otherwise specified. Homogenization buffer
was 25 mM Trizma, 0.5 mM EDTA, 5 mM histidine, 0.25 M sucrose, pH 7.4.
Trizma was used as an alternative to PBS to reduce background signal in G6Pase
assay. Storage buffer, G6Pase assay buffer, and Taussky-Shorr color reagent were
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prepared as described earlier herein for dogs. Mycophenolic acid glucuronidation
assay buffer was 0.1 M phosphate buffer containing 3.45 mM MgCl2, 1.15 mM
EDTA, and 115 mM saccharic acid lactone (Kilford et al., 2009).
Sample Collection and Storage. Normal human kidney cortex pieces from
nephrectomy patients (n = 20), excised from the pole of the kidney contralateral to
the tumor site, were obtained by the Biobank, Central Manchester University
Hospitals NHS Foundation Trust (CMFT), UK. Kidney cortex pieces were snap-
frozen within 1 h of excision and stored at280C. Informed consent was obtained
from donors. Ethical approval for this research was obtained from National
Research Ethics Service (NRES) Committee London, Camberwell St. Giles (REC
ref. 13/LO/1896), with samples stored under Human Tissue Authority license.
Human kidney cortex homogenates (n = 18) were prepared from renal cortex
from healthy kidneys unsuitable for transplant at Newcastle University, obtained
under NRES ethical approval with informed consent from the donors. Homogenates
from Newcastle University were stored at280C until used. No information on the
time delay between organ isolation and storage was available.
Homogenate and Microsomal Preparation. A single batch of homogenate
and microsomes was prepared for each donor, with the exception of donor
CMFT6, for which an initial batch was prepared for use in preliminary
experiments; data generated during preliminary experiments were not included
in analyses of the main data set. Frozen human kidney cortex samples were
rapidly thawed at 37C, washed in PBS, blotted dry, and weighed. Finely minced
human kidney cortex samples (1.2–6.7 g) were homogenized with 4 to 5 ml/g of
mince of homogenization buffer. Homogenization was initially with a rotor-stator
homogenizer (Dremel UK, Middlesex, UK). Bursts of 20 s with 30 s rest on ice
were used until no intact pieces of kidney cortex mince were apparent upon visual
assessment. This typically required three to six bursts, depending on the starting
weight of the kidney cortex mince. Samples were further homogenized using an
Omni Ruptor 400 Ultrasonic homogenizer (Omni International, Kennesaw, GA)
for two bursts of 10 s each, separated with a 30-s resting period on ice.
Homogenate was filtered through 170-mm nylon mesh (Plastok Associates).
Homogenates from Newcastle University were thawed rapidly at 37C and then
kept on ice until use. Total kidney cortex homogenate volumes were measured,
and aliquots were stored on ice for analysis.
Human kidney cortex homogenates were centrifuged at 9000g at 4C for
15 min using an Optima TLX-120 Ultracentrifuge with an MLA-80 rotor
(Beckman Coulter UKLtd). After removing aliquots for analysis (1 to 2ml, stored
on ice), 9000g supernatants (S9) were further centrifuged at 105,000g at 4C for
70 min. Aliquots of the cytosol were stored on ice for analysis. The microsomal
pellet was resuspended in storage buffer using a vortex mixer and pipette.
Aliquots were taken for protein content analysis; remaining microsomal samples
were stored at 280C.
Microsomal and Cytosolic Protein Markers in Human Samples. On the
day of microsomal preparation, protein content in homogenate, S9, microsomes,
and cytosol was determined in triplicate using aMicro Bicinchoninic Acid Protein
Assay Kit (Pierce Biotechnology no. 23227) according to the manufacturer’s
instructions. Absorbance (562 nm) was measured with a SpectraMax 190 plate
reader (Molecular Devices, Sunnyvale, CA), with BSA used as calibration
standard. All activity assays were performed on samples that had undergone four
or fewer freeze-thaw cycles. G6Pase activity was measured in duplicate using
the spectrophotometric method described earlier herein for the dog samples;
absorbance (660 nm) was measured with a SpectraMax 190 plate reader.
Interassay variability was assessed using four batches of human kidney cortex
homogenate and microsomes from three kidney cortex samples, for which
G6Pase activity was measured twice. Interbatch variability was assessed through
preparation of two batches of homogenate and microsomes (donor CMFT6) on
different days. Interbatch and interassay variability were compared by measuring
G6Pase activities for each batch in two separate assays, with one of these assays
common for both batches.
GST activity was measured in human kidney cortex homogenate, microsomes,
and cytosol samples using an assay kit (Sigma no. CS0410) according to the
manufacturer’s instructions with the following modification: samples were
initially prepared in 0.1 M sodium phosphate buffer, pH 6.5, with 1% Triton
X-100 (Ji et al., 2002) owing to inadequate volume of sample buffer providedwith
the assay kit. GST activity wasmeasured using protein concentrations of 10mg/ml
(determined after preliminary optimization experiments using rat kidney samples),
with substrate concentrations of 100 and 200 mM for 1-chloro-2,4-dinitrobenzene
and L-glutathione, respectively. Absorbance (340 nm) wasmeasured at appropriate
time points up to 10 min using a SpectraMax 190 plate reader. Results were
processed with Microsoft Excel. GST activity was expressed as nmol/min/mg
protein based on the initial linear rate of ΔA340, using an extinction coefficient
(ΔA340) of 9.6 mM21 cm21 for 1-chloro-2,4-dinitrobenzene conjugate.
Estimation of Microsomal and Cytosolic Protein Contents of Tissues
Various parameters (Table 1), including yields of total protein and microsomal
marker in subcellular fractions from a microsomal preparation, as well as the
recovery factor of the microsomal protein, were calculated (eq. 1–4). This
approach allowed correction for the removal of material as aliquots of homogenate
and S9 before differential centrifugation steps when calculating the theoretical
yield of the protein marker (eq. 2). The latter represents the marker activity/content
if there was a complete recovery of the marker that was present in the homogenate
(eq. 2). Actual (eq. 3) and theoretical yield of the marker activity/content in the
microsomal fraction obtained from the homogenate were used to calculate
MPPGK (eq. 5). In addition, a microsomal or cytosolic protein enrichment factor
was calculated based on the marker activity/content of the subcellular fraction
relative to that of the homogenate (eq. 6):
Abs Protx ¼ ½Protx  Vx;total ð1Þ
YieldMarker;Theor ¼ MarkerHom  Abs ProtHom  VHom;total2VHom;aliquotVHom;total
 VS9;total2VS9;aliquot
VS9;total
ð2Þ
YieldMarker;Actual ¼ Markerx  Abs Protx  VMic;total ð3Þ
Recoveryx ¼ YieldMarker;actualYieldMarker;theor ð4Þ
MPPGK ¼ Abs ProtMic
RecoveryMic WKid ð5Þ
Enrichmentx ¼ MarkerxMarkerhom ð6Þ
The preceding equations are applicable for calculation of the cytosolic protein
recovery and CPPGK in conjunction with appropriate cytosolic protein markers.
GST can be considered a cytosolic marker, with a limitation that some GSTs are
also found in the endoplasmic reticulum component of the microsomal fraction
(Hayes and Pulford, 1995; Song et al., 2015). In an exploratory assay, substantial
GST activity was noted in human kidney cortex microsomes, suggesting that GST
activity in human kidney cortex homogenate was attributable to both cytosolic
and microsomal isoforms (Supplemental Fig. S3). Therefore, MPPGK for each
human kidney donor, estimated using G6Pase activity as microsomal protein
marker, was used to account for the GST activity attributable to the microsomal
GST in each human kidney cortex homogenate (eq. 7–9). This involved
calculating the total microsomal protein and then the microsomal GST activity in
the homogenate, which was subtracted from the theoretical GST yield (calculated
using eq. 2). This corrected theoretical GST activity yield in homogenate was
compared with the actual GST activity yield in the cytosolic fraction (eq. 3) to
account for cytosolic protein losses during the fractionation procedure and
subsequently CPPGK (eq. 10 and 11).
To ensure that the estimates of MPPGK and CPPGK were physiologically
feasible, their combined value was compared with the amount of homogenate
protein obtained per gram of kidney cortex for each donor. The combined value
should reflect the S9 protein content per gram of kidney cortex. Therefore, the
value calculated was expressed as the percent contribution of the S9 fraction to the
overall protein in the homogenate (eq. 12):
Mic ProtHom ¼ MPPGK WKid ð7Þ
Mic GSTHom ¼ Mic ProtHom  GSTMic ð8Þ
YieldGST;Theor;corrected ¼ YieldGST;Theor2Mic GSTHom ð9Þ
RecoveryCyt ¼ YieldGST ;actualYieldGST;theor;corrected ð10Þ
CPPGK ¼ Abs ProtCyt
RecoveryCyt WKid ð11Þ
S9 contributionHom  5 
MPPGK1CPPGK
Abs ProtHom=WKid
100ð%Þ ð12Þ
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Mycophenolic Acid Glucuronidation Depletion Assay in Human
Kidney Microsomes
Mycophenolic acid was selected as a clinically relevant marker to assess the
metabolic activity of the prepared human kidney cortex microsomes, and
investigate the variability of UGT activity within the kidney cortex samples.
Mycophenolic acid has previously been shown to undergo glucuronidation
in vitro in human liver, intestine, and kidney microsomes (Picard et al., 2005;
Cubitt et al., 2009; Gill et al., 2012), with UGT1A9 identified as themajor enzyme
involved in its renal metabolism and UGT2B7 having a lesser role (Picard et al.,
2005). Microsomal glucuronidation substrate depletion intrinsic clearance assays
were performed for a subset of 20 donors (CMFT) using a method previously
reported (Gill et al., 2012), including a no-cofactor control. The mycophenolic
acid reactions were performed at a substrate concentration of 1 mM, which was
expected to be under linear conditions considering the reported Km values for
UGT1A9 and UGT2B7 (Bernard and Guillemette, 2004; Picard et al., 2005).
Because of low availability of microsomal protein, only one replicate for each
donor was performed; each assay was done in triplicate. The assay was also
performed in XenoTech pooled human kidney microsomes (13 donors, mixed
gender). Human kidney microsomes (0.25 mg/ml) were activated by preincuba-
tion with 50 mg/mg protein alamethicin in assay buffer for 15 min on ice.
Mycophenolic acid was preincubated with alamethicin-activated microsomes and
bovine serum albumin (BSA; assay concentration 1%) for 5 min in assay buffer at
37C shaking at 900 rpm (Eppendorf thermomixer; Hamburg, Germany)).
Reaction was initiated by the addition of uridine-diphosphate-glucuronic acid at
a final assay concentration of 5 mM. After incubation at 37C with shaking at
900 rpm, aliquots of the incubation mixture were quenched in two volumes of ice-
cold acetonitrile containing 1 mMwarfarin (internal standard) at eight time points
between 0 and 60 min inclusive. Minimal depletion of mycophenolic acid was
observed after 60 min at 0.25 mg/ml for donor CMFT1; therefore, a modified
assay, with a protein concentration of 0.5 mg/ml and time points extended to
90 min, was used for this donor. Quenched samples were stored at 220C for at
least 1 h and then centrifuged at 9000 rpm for 20 min. Aliquots of supernatant
were analyzed by liquid chromatography-mass spectrometry (LC-MS/MS)
for mycophenolic acid concentration using matrix-matched calibration standards
(0–5 mM). To preserve individual donor human kidney cortex microsome
samples, XenoTech pooled human kidney microsomes were used for preparing
calibration standards.
LC-MS/MS analysis was performed using an Agilent 1100 HPLC system
(Stockport, Cheshire, UK) coupled to a Micromass Quattro Ultima triple
quadruple mass spectrometer (Waters, Elstree, Hertfordshire, UK). LC was
performed using a Luna C18 (3m, 50 4.6 mm) column (Phenomenex, Torrance,
CA) with appropriate elution gradient (Supplemental Table S1) and a flow rate of
1 ml/min. The retention times of mycophenolic acid and warfarin were 4.21 and
4.49 min, respectively. For MS, source temperature, desolvation temperature,
desolvation gas flow rate, cone gas flow rate, and capillary voltage were 125C,
350C, 600 l/h, 50 l/h, and 3.5 kV, respectively. Selective reaction monitoring of
mycophenolic acid and warfarin with negative electrospray ionization was
performed; transitions of precursor to product ions (m/z) were 318.90→191.10
for mycophenolic acid and 306.90→161.05 for warfarin. Cone voltage and
collision voltage were 90 V and 25 eV for mycophenolic acid and 130 V and
19 eV for warfarin, respectively.
Genotyping of Selected Polymorphisms in UGT1A8, 1A9, and 2B7
Genotyping of 20 human kidney cortex samples for selected single-nucleotide
polymorphisms (SNPs) genes encoding the UGT1A8 (rs17863762), UGT1A9
(rs17868320, rs2741045, rs6714486, rs72551330, rs2741046), and UGT2B7
(rs7438135) enzymes was performed by NewGene (Newcastle upon Tyne, UK).
These SNPs were selected on the basis of clinical data indicating that they are
associated with interindividual variability in pharmacokinetic and pharmacody-
namic endpoints of mycophenolic acid (Picard et al., 2005; Prausa et al., 2009;
Fukuda et al., 2012). Briefly, after DNA extraction from tissue using a Promega
Maxwell automation platform, polymerase chain reaction, and extension reaction,
analysis was performed on the Agena MassARRAY4 platform. Each sample was
run in duplicate.
Prediction of In Vivo Mycophenolic Acid Glucuronidation Clearance
Human kidney cortex microsomal intrinsic clearance (CLint,UGT,HKM;
ml/min/mg of microsomal protein) for mycophenolic acid was calculated
from the elimination rate constant (k; min21) and the microsomal protein
concentration of the incubation (mg/ml) using eq. 13; k was calculated from the
slope of the linear correlation of the natural log-fraction remaining (average of
triplicate incubations at each time point) versus time. In vitro CLint,UGT,HKM
data for each donor were corrected for the fraction unbound in the incubation
TABLE 1
Parameters used in calculation of MPPGK and CPPGK from human and dog kidney cortex samples
Parametera Description Units
Abs_Protx Absolute protein yield in homogenate or subfraction (x) mg
[Prot]x Protein concentration of homogenate or subfraction (x) mg/ml
Vx, total Volume of homogenate or subfraction (x), before aliquots are
taken for analysis where applicable
ml
Vx, aliquot Volume of homogenate or subfraction aliquot taken for analysis ml
Markerx Activity or content of subcellular protein marker in homogenate,
microsome, or cytosol (x)
nmol/mg protein (CYP)
nmol/min/mg protein (G6Pase)
nmol/min/mg protein (GST)
WKid Weight of starting kidney tissue mince g
YieldMarker, theor Theoretical yield of subcellular protein marker from
homogenate, accounting for aliquot removal
nmol (CYP)
nmol/min (G6Pase)
nmol/min (GST)
YieldMarker, actual Actual yield of subcellular protein marker from homogenate nmol (CYP)
nmol/min (G6Pase)
nmol/min (GST)
RecoveryX Percent recovery %
Enrichmentx Enrichment factor of subcellular protein (x)
Mic_ ProtHom Amount of microsomal protein in the homogenate, based on
starting tissue weight and the MPPGK.
mg
Mic_GSTHom Activity of GST in the homogenate attributable to microsomal
isoform(s)
nmol/min
YieldGST,theor,corrected Theoretical cytosolic GST activity yield. The GST activity yield
in the homogenate that was attributed to the cytosolic fraction
(i.e., corrected for the microsomal GST activity)
nmol/min
S9_contributionHom Theoretical % contribution of the microsomal protein and
cytosolic protein (i.e., S9 fraction) to overall protein in
homogenate
%
aWhere x represents either homogenate (Hom), 9000g supernatant (S9), or microsomes (Mic). Equations are stated in the Materials and Methods (eq. 1–12).
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(fu,inc; 0.18 at all microsomal protein concentrations, obtained in the presence
of 1% BSA, as previously reported) (Gill et al., 2012) to calculate the unbound
intrinsic clearance (CLint,u,UGT,HKM). The CLint,u,UGT,HKM data were scaled using
MPPGK and average kidney weight of 4.5 g/kg of body weight. Prediction
of in vivo mycophenolic acid renal glucuronidation clearance (CLR,met,UGT)
was done using the well stirred kidney model (eq. 14), fraction unbound in
plasma (fu,p) and blood-to-plasma concentration ratio (RB) of 0.01 and 0.6,
respectively (Gill et al., 2012).
The IVIVE of mycophenolic acid CLR,met,UGT was performed using two
different scenarios for scaling factors, as summarized in Table 2. An MPPGK
of 11.1 mg/g kidney was applied in Scenario 1; this value was calculated as
the weighted (by donor number) mean of literature values reported by studies
that used mixed kidney (i.e., cortex and medulla) or unspecified region
(Al-Jahdari et al., 2006; Knights et al., 2016). In Scenario 2, the CLint,u,UGT,HKM
values for each donor were scaled by the corresponding MPPGK value
obtained for kidney cortex in the current study. Prediction of in vivo
metabolic clearance also requires information on organ weight and blood flow;
for Scenario 1, whole kidney weight and renal blood flow (QR) were used,
whereas cortex weight and cortical blood flow were used in Scenario 2 (68% and
80% of the respective values for the whole kidney (Lerman et al., 1996; Vallée
et al., 2000) (Table 2).
Predicted overall mycophenolic acid glucuronidation clearance rates were
calculated as the sum of the renal (eq. 14) and hepatic (CLh,met,UGT)
glucuronidation clearances (eq. 15). Analogous to renal metabolism, CLh,met,
UGT was calculated with the well stirred liver model, using scaled CLint,u,UGT,HLM
of 9.32 ml/min/g liver, obtained under the same BSA conditions in vitro, as
reported inGill et al. (2012).MPPGL of 40mg/g of liver, liver weight of 21.4 g/kg
of body weight, and hepatic blood flow (Qh) of 20.7 ml/min/kg were used, as
previously reported (Gill et al., 2012). Observed mycophenolic acid glucuroni-
dation clearance (CLUGT) of 3.97 ml/min/kg (Gill et al., 2012) was used to assess
the predictive performance of the IVIVE. This value is based on a plasma i.v.
clearance of 2.49ml/min/kg corrected for the renal excretion (0.01ml/min/kg) and
the fraction metabolized by UGT (fm,UGT of 0.95, obtained from urinary excretion
data):
CLint;UGT ;HKM ¼ k  Vamount of microsomal proteinin in cubation ð13Þ
CLR;met;UGT ¼
QR  fu;p

RB  CLint;u;UGT;HKM
QR þ fu;p

RB  CLint;u;UGT;HKM
ð14Þ
CLUGT ¼ CLh;met;UGT þ CLR;met;UGT ð15Þ
Data Analysis
CYP content and microsomal protein per gram of intestine (MPPGI) data for
14 dog intestinal samples were provided by Dr Oliver Hatley (manuscript in
preparation). These data were obtained from different regions of the intestine, with
each region being defined as one sixth of the entire intestine by length. The initial three
regions were defined as proximal 1, 2, and 3; the final region was defined as distal.
Average (mean) values were calculated, with variability estimated using the
coefficient of variation (CV; %). Interassay variability (%) was estimated as the
average between-assay CV for each set of samples. Data were analyzed using MS
Excel. Student’s t test (paired, two-tailed) was used to statistically comparemeans;
P, 0.05 was considered significant. The unpaired t test was used for comparison
of CYP content in homogenates prepared from fresh and frozen kidney cortex
owing to differences in the number of samples in each group.
Results
Characterization and Optimization of Protein Marker Assays
In the initial phase of the study, the validity of three different markers
was investigated, together with assessment of assay reproducibility.
CYP Content Assay. Compared with the liver, 450 nm absorbance
signal in the sodium dithionite difference spectra was generally weak in
kidney cortex but sufficient for quantification. On average, the interassay
variability of CYP content was 10% and 5% for homogenate and
microsomes, respectively, and 14% for the calculated microsomal
protein enrichment factor. Based on data from one dog, for which two
separate batches of microsomes were prepared, the interassay variability
in CYP content measurement was similar to the apparent interbatch
variability (Supplemental Fig. S4). This trend was also noted for the
calculated CYP content enrichment factor (approx. 12% variability for
interbatch and interassay).
G6Pase Activity Assay. Dog kidney cortex G6Pase activity
appeared to be linear with respect to protein concentration in both
homogenate and microsomes, but it was not directly proportional (i.e.,
intercept  0) (Supplemental Fig. S5). Activity could not be reliably
quantified at the lower protein concentrations (#0.1 mg/ml) for
homogenate. The resultant microsomal protein recovery factors
calculated for each assay protein concentration did not appear to
show protein dependency. Therefore, G6Pase activity was considered a
suitable marker to estimate microsomal protein losses. The average
interassay variability (CV) of G6Pase activity was 20.6% and 19.8% for
homogenate and microsomes, respectively, whereas G6Pase activity
enrichment factor interassay variability was 14%.
In human kidney cortex, the interassay variability of G6Pase assay
appeared to be greater than the interbatch variability (Supplemental Fig.
S6). The average interassay variability in G6Pase activity was 15% and
19% for homogenate and microsomes, respectively, which resulted in an
average interassay variability of 18% for the calculated G6Pase activity
enrichment factor (range, 3%–39%).
GST Activity Assay. GST activity was nonlinear with respect to
protein concentration in both rat kidney homogenate and cytosol
(Supplemental Fig. S7). GST activity could be reliably quantified at
the lower protein concentrations (#5 mg/ml), albeit with lower re-
producibility in homogenate. There was low interassay variability at the
protein concentration selected for the final assay (10 mg/ml). Assay
protein concentration did not appear to affect the apparent enrichment
factor (Supplemental Fig. S7). Therefore, GST activity was considered a
suitable marker for cytosolic protein.
Estimation of Microsomal Protein Content in Dog Kidney Cortex
and Liver and Comparison with Intestine
Liver and kidney cortex samples were obtained from a total of
17 dogs. Average CYP content in dog kidney cortex homogenate
prepared from frozen kidney tissue was 0.056 nmol/mg protein (n = 17),
which was significantly lower (P , 0.05) than that in homogenate
prepared from fresh kidney cortex tissue (0.086 nmol/mg protein;
TABLE 2
Physiologic values used for CLR,met,UGT predictions using IVIVE in different scenarios
Parameter (U) Scenario 1 (Whole Kidney) Scenario 2 (Kidney Cortex)
MPPGK (mg/g kidney) 11.1a Donor specificb
Kidney weight (g/kg body weight) 4.5 3.1
Renal blood flow (ml/min/kg body weight) 16.4 13.2
aWeighted (by number of donors) mean of values reported for microsomes prepared from mixed kidney or unspecified region
(Al-Jahdari et al., 2006; Knights et al., 2016).
bFig. 5 and (Supplemental Table S3).
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n = 14) (Table 3). Both CYP content and G6Pase activity were
statistically significantly lower (P, 0.05) in dog kidney cortex compared
with corresponding livers (data were available only for frozen tissue
samples). Mean CYP content for dog kidney cortex microsomes was
more than 3-fold greater than for intestinal microsomes (samples were
available from fresh tissue only). No trends were apparent in the CYP
content or G6Pase activity between the liver and kidney cortex, based
on visual assessment of the data.
Mean MPPGK in dog kidney cortex was 43.1 mg/g kidney cortex
when CYP content was used as microsomal protein marker and samples
were prepared from fresh kidney cortex (Table 3); individual values
ranged from 27.4 to 58.6 mg/g kidney cortex (Supplemental Table S2).
This was on average 27% higher than the corresponding value when
samples were prepared from frozen kidney cortex. MPPGK was on
average 18% or 31% lower than MPPGL when CYP content or G6Pase
activity was used as microsomal protein marker, respectively (Table 3).
This difference varied between dogs, but no apparent correlation was
found inMPPGK andMPPGL (Fig. 2). BothMPPGL andMPPGKwere
consistently greater thanMPPGI for all regions of intestine studied, with
no trends apparent, either when considering data for each region
separately or data for all intestinal regions collectively. No clear trends
between eitherMPPGLorMPPGKand factors such as age or dogweight
were apparent (data not shown). Dog microsomal protein content was
lower when using CYP content than when using G6Pase activity as
microsomal marker, by 23% forMPPGK and 35% forMPPGL (Table 3).
Bland-Altman plots show that the 95% confidence intervals for the mean
difference between the markers do not overlap with the line of unity
(difference = 0), suggesting systematic bias (Fig. 3).
Estimation of MPPGK and CPPGK in Human Kidney Cortex
Average G6Pase activities of human kidney cortex homogenate and
microsomes were 8.1 and 27.9 nmol/min/mg protein (n = 38 kidney
cortex samples), with CVs of 61% and 53%, respectively (Fig. 4A). The
G6Pase activities were higher in samples obtained from Newcastle
University (9.2 and 31.1 nmol/min/mg protein in homogenate and
microsomes, respectively; n = 18) compared with those obtained from
the CMFT Biobank (7.1 and 24.9 nmol/min/mg protein in homogenate
andmicrosomes, respectively; n = 20). Average GST activities of human
kidney cortex homogenate, microsomes, and cytosol were 217, 106, and
318 nmol/min/mg protein, respectively (n = 38); CVs for those samples
were between 40% and 44% (Fig. 4B). Analogous to G6Pase, GST
activities were higher in samples obtained from Newcastle University
(234, 112, and 357 nmol/min/mg protein in homogenate, microsomes,
and cytosol; n = 18) compared with those obtained from CMFT Biobank
(202, 100, and 284 nmol/min/mg protein in homogenate, microsomes, and
cytosol, respectively; n = 20).
Average MPPGK in humans obtained from all 38 samples was
26.2 mg of protein/g kidney cortex, with a CV of 27% (Fig. 5 and
Table 4). Microsomal GST activity, scaled using MPPGK to units of
nmol/min/g kidney cortex, represented on average 14.5% of the GST
activity yield in human kidney cortex homogenate. After correction for
activity attributable to microsomal GST isoform(s) in the homogenate,
average human CPPGKwas 53.3 mg protein/g kidney cortex, with 31%
CV (Fig. 5 and Table 4). There was no apparent trend betweenMPPGK
and CPPGK (Supplemental Fig. S8). The average S9 protein per gram
of kidney cortex (i.e., the sum of MPPGK and CPPGK) was 79.5 mg
protein/g kidney cortex (n = 38). Theoretical contribution of the S9
protein to the protein content of homogenate was 89% on average,
although the value exceeded 100% for seven of 38 samples (Fig. 5).
Based on the subset of 20 donors for whom demographic data were
available, no trends between human MPPGK or CPPGK and factors,
such as age, gender, and weight, were found (not shown). MPPGK and
CPPGK of samples from CMFT Biobank were each significantly greater
than the values obtained from samples from Newcastle University (P,
0.05; two-tailed t test). Observed MPPGK variability for CMFT
Biobank samples was one third lower than Newcastle University
samples (Table 4).
In Vitro Glucuronidation of Mycophenolic Acid by Human Kidney
Cortex Microsomes and IVIVE
Mycophenolic acid CLint,u,UGT,HKM was measured in 20 CMFT
Biobank individual human kidney cortex microsomes and XenoTech
pooled kidney microsomes (Supplemental Fig. S9). Average CLint,u,UGT,HKM
in the 20 donors was 1061 ml/min/mg microsomal protein, with
43% CV and range of 93–1896ml/min/mgmicrosomal protein for donor
CMFT1 and CMFT5, respectively. The average value was approx-
imately 2-fold lower compared with mycophenolic acid CLint,u,UGT,HKM
obtained in the commercially sourced pooled kidney microsomes in the
current study (1843 ml/min/mg protein). No depletion of mycophenolic
acid was observed in the no-cofactor control for any of the donors
investigated. A positive correlation between mycophenolic acid
CLint,u,UGT,HKM and G6Pase activity was noted (Supplemental Fig. S10).
A weak trend between mycophenolic acid CLint,u,UGT,HKM and UGT2B7
genotype2900G. A (rs7438135) was noted (AA. GA. GG (Fig. 6);
the low number of donors relative to the number of polymorphisms
tested precluded statistical assessment of this trend. This trend was
reflected in the predicted CLUGT, as six of seven of the donors with
predicted/observed CLUGT , 1.0 (Scenario 2) had the GG or GA
genotype. No other trends between genotype and mycophenolic acid
CLint,u,UGT,HKM were apparent for the polymorphisms investigated
(Supplemental Table S3).
Scaled mycophenolic acid CLint,u,UGT,HKM (per gram of organ weight)
was on average 2.6-fold greater when the donor-specific MPPGK values
measured using cortex tissue in the current study were applied (i.e.,
Scenario 2) than when the MPPGK value calculated for whole kidney
was used (i.e., Scenario 1) (Table 5). These differences were reflected
TABLE 3
CYP content, G6Pase activity, and MPPG measured in homogenate and microsomal samples prepared from fresh dog kidney cortex, frozen dog kidney cortex, and
frozen dog liver
Average values are presented, with CVs in parentheses. G6Pase activity was not measured in samples prepared from fresh dog kidney cortex. Data for individual dogs are presented (Supplemental
Table S2).
CYP Content (nmol/mg Protein) G6Pase Activity (nmol/min/mg Protein) MPPG (mg/g Tissue)
Homogenate Microsomes Homogenate Microsomes CYP content G6Pase activity
Fresh tissue (n = 14) Dog kidney cortex 0.086 (24%) 0.205 (23%) Not measured Not measured 43.1 (22%) Not measured
Dog intestinea Data not available 0.059 (27%) Not measured Not measured 6.5 (61%) Not measured
Frozen tissue (n = 17) Dog kidney cortex 0.056 (16%) 0.230 (15%) 19.9 (16%) 62.1 (16%) 33.9 (18%) 44.0 (16%)
Dog liver 0.113 (19%) 0.665 (20%) 23.8 (15%) 91.2 (18%) 41.1 (12%) 63.6 (18%)
aData for dog intestine were provided by Dr Oliver Hatley (manuscript in preparation) and represent data pooled from several intestinal regions.
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in the assessment of the importance of renal glucuronidation relative
to liver, i.e., the kidney:liver ratios for CLint,u,UGT (calculated using
published data for liver, obtained using comparable in vitro assay
conditions to the current study, i.e., 1% BSA) (Gill et al., 2012)
(Fig. 7A).
Underprediction of mycophenolic acid CLUGT was observed when
only the hepatic contribution to glucuronidation clearance was consid-
ered (Fig. 7B). Accounting for both the hepatic and renal contributions
improved the prediction of CLUGT for both Scenario 1 and 2. Whereas
for Scenario 1, uniformity in glucuronidation activity throughout kidney
is assumed (common assumption in the literature (Gill et al., 2012;
Knights et al., 2016), Scenario 2 has the assumption that glucuronidation
occurs only in cortex (by applying cortex tissueweight and blood flow in
the well stirred kidney model). Predicted CLUGT was approximately
15% greater in Scenario 2 compared with Scenario 1 (Table 5), as
demonstrated in the respective predicted/observed ratios (Scenario 1:
0.93; Scenario 2: 1.06) (Fig. 7B). Application of the cortical MPPGK
obtained in the current study for the whole kidney (in conjunction with
kidney weight and blood flow) would increase the predicted CLR,met,UGT
by 43% compared with that of Scenario 2.
Discussion
Microsomal and cytosolic protein contents in tissues of human and
preclinical species are used as scaling factors for IVIVE of microsomal
metabolism data to predict drug in vivo clearance. Information on the
microsomal scalar in human kidney is limited compared with the liver
(Scotcher et al., 2016b). Data on the cytosolic protein in human kidney
and the microsomal and cytosolic protein in preclinical species (that
have explicitly accounted for protein recovery) are lacking.
In the current study, the microsomal protein content of dog kidney
cortex was measured using two different microsomal protein recovery
markers and compared with the corresponding values in matched liver
and intestine. Further, the microsomal and cytosolic protein content was
measured in 38 human kidney cortex samples. For 20 of these samples,
the functional activity was assessed using a mycophenolic glucuroni-
dation substrate depletion assay. These data were used to assess the
impact of different MPPGK values, as well as different assumptions
concerning the contribution of whole kidney versus only the cortex to
renal drug glucuronidation, on prediction of in vivo mycophenolic acid
glucuronidation clearance.
Suitability of Microsomal and Cytosol Protein Markers for
Correction of Protein Losses
Ensuring complete homogenization of kidney tissue, while also
limiting contamination of microsomes with other sources of haemo-
proteins such as mitochondria, can be challenging. When measuring
CYP content in kidney cortex, the low CYP levels and potential for
spectral interference from contaminating haemoproteins make accu-
rate quantification challenging (Jakobsson and Cintig, 1973; Ohno
et al., 1982). Preliminary experiments showed minor spectral
interference in the dithionite difference spectra, and therefore bias in
the CYP content measurements and subsequent MPPGK estimates was
unlikely when considered alongside the interassay variability (Matsubara
et al., 1976). Furthermore, the dog kidney cortex microsomal CYP
content measured in the current study using the dithionite difference
method (Table 3) was comparable to a value reported using a customized
spectral method (0.223 nmol/mg protein) (Ohno et al., 1982). CYP
content measured in dog liver was also in good agreement with
previously published values (Smith et al., 2008). Therefore, the standard
dithionite difference spectra approach was deemed appropriate to be used
in the current study.
Fig. 3. Bland-Altman plots: difference in MPPG measured using CYP content
versus G6Pase activity as microsomal protein marker. Points on graphs represent
measurements made in kidney cortex (A) or liver (B) microsome and homogenate
samples. Blue lines represent mean (solid) and 95% confidence interval of mean
(dashed) difference between MPPGs. Red dotted lines represent 95% limits of
agreement. Thin black lines represent line of unity.
Fig. 2. Comparison of MPPGK and MPPGL in dogs (n = 17 dogs) using either
CYP content (black circle) or G6Pase activity (blue cross) as the microsomal protein
marker. Each point represents microsomal scalar measured using a single batch of
homogenates and microsomes from a single dog.
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G6Pase activity was selected as a possible alternative microsomal
protein marker for correction of protein losses during centrifugation. The
estimated microsomal protein recoveries in dogs using this marker
(frozen tissue) were lower relative to CYP content in both liver (38% for
G6Pase and 58% for CYP content) and kidney cortex (40% for G6Pase
and 53% for CYP content). Subsequently, the microsomal protein
Fig. 4. Marker activities measured in 38 human
kidney cortex samples. (A) G6Pase activity in
homogenate and microsomes. (B) GST activity
homogenate, microsomes, and cytosols. CMFT
number and NC number indicate samples
acquired from the CMFT Biobank or New-
castle University, respectively. Each bar typi-
cally represent n = 1 measurements per donor,
although for some samples bars represent the
average of n = 2 measurements. Individual
values are listed (Supplemental Table S3).
Fig. 5. MPPGK and CPPGK protein content of kidney cortex and homogenate protein yields in 38 human kidney cortex samples. Combined value of MPPGK and CPPGK
in each donor represents the estimated S9 protein per gram of kidney cortex; this value should not exceed the homogenate protein yield to be physiologically plausible.
CMFT number and NC number indicate samples acquired from the CMFT Biobank or Newcastle University, respectively. Each bar represents n = 1 batch of
homogenate/microsomes/cytosol per donor. Individual values are listed (Supplemental Table S3).
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content estimates were higher when using G6Pase activity. Although
G6Pase is present in the nuclear envelope, it is at very low levels relative
to the endoplasmic reticulum and unlikely to fully explain the marker
related differences in microsomal protein content (Kartenbeck et al.,
1973; Nordlie, 1979). Despite the potential for overestimation of MPPG
values using G6Pase, this marker was preferred for human samples over
CYP content, because of the low sensitivity of the CYP content assay
and expected higher biologic variability than in dogs.
A positive correlation between G6Pase activity and mycophenolic
acid CLint,u,UGT,HKM was observed (Supplemental Fig. S10). Tissue
storage would be an unlikely cause, as CMFT kidney cortex samples
were snap-frozen within 1 h of excision. Preliminary comparisons of
G6Pase activity in different batches of human kidney cortex microsomes
from the same donor showed good reproducibility (Supplemental Fig.
S6), confirming that the homogenization procedure was consistent.
Coregulation of G6Pase and UGT enzymes is a more likely explanation
for the observed correlation between G6Pase activity and mycophenolic
acid CLint,u,UGT,HKM. Members of the hepatocyte nuclear factors
families of transcription factors (HNF1 and HNF4) may be involved in
regulating the expression of G6Pase (Lin et al., 1997; Rajas et al.,
2002), UGT1A9 (Ramírez et al., 2008; Hu et al., 2014b), and UGT2B7
(Ramírez et al., 2008; Hu et al., 2014b). In addition, D-glucose and
glucose-6-phosphate (substrate and product of G6Pase mediated
reaction) and uridine-diphosphate-glucuronic acid (cofactor for UGT-
mediated glucuronidation) are closely positioned in the cellular metabolic
pathway (http://biochemical-pathways.com/#/map/1).
Both alcohol dehydrogenase and GST activity have been suggested as
potential cytosolic protein markers (Cubitt et al., 2011). In the current
study, implementation of the alcohol dehydrogenase activity assay was
ineffective (data not shown). Therefore, GST activity was used as the
human cytosolic protein marker, despite the presence of some GST also
in the microsomes (Song et al., 2015). GST activity in human kidney
cortex cytosol was higher than that in microsomes, in agreement with
similar findings for human liver (Prabhu et al., 2004). Average GST
activities in human kidney cortex microsomes were higher than a
literature value by approximately one order of magnitude (Morgenstern
et al., 1984); conversely, GST activities in human kidney cortex cytosols
were on average lower than previously reported values for normal
human kidney (Simic et al., 2001, 2003). Ignoring the proportion of GST
activity in homogenate attributed to microsomal isoforms (14.5%) when
calculating the cytosolic protein recovery would result in an increase in
the average estimated CPPGK by 13%. In the extreme case, this 13%
differencewill contribute to potential systematicmisprediction of in vivo
metabolic clearance when using CPPGK as an IVIVE scaling factor for
in vitro cytosolic metabolism data.
Species and Tissue Differences in Subcellular Protein
Content Estimates
The direct comparison of microsomal content of liver and kidney
cortex from samples obtained from the same animals showed no
correlation between the scalars, although MPPGL was on average
45% higher thanMPPGK (G6Pase as marker). The mean MPPGK value
in dog (44.0 mg/g kidney cortex) was higher than the corresponding
value in human (26.2 mg/g kidney cortex), in agreement with literature
data suggesting a similar relationship for MPPGL (Barter et al., 2007;
Heikkinen et al., 2012, 2015). The variability observed in MPPGK in
dogs was lower than that in humans, despite similar interassay variability
in G6Pase activities, indicating greater biologic variability in human
MPPGK. This trend is expected because of the higher genetic and
environmental variability encountered in humans compared with that in
laboratory animals.
The number of kidney cortex samples used to estimate human
MPPGK in the current study (n = 38) was greater than the entire
combined samples reported so far in the literature (n = 23 across four
studies) (Scotcher et al., 2016b) and therefore provides a more reliable
indicator of true biologic variability in this microsomal scalar. Overall,
TABLE 4
MPPGK, CPPGK, and S9PPGK for samples prepared from frozen human kidney. Data for individual donors are presented (Supplemental Table S3)
MPPGK (mg Protein/g Kidney Cortex) CPPGK (mg Protein/g kidney Cortex) S9PPGK (mg Protein/g Kidney Cortex)
All donors (n 5 38)
Average 26.2 53.3 79.5
CV (%) 27 31 24
Range 9.0–42.6 30.6–123.2 45.9–149.9
CMFT donors only (n 5 20)
Average 28.4 60.3 88.7
CV (%) 21 30 21
Range 20.2–42.6 38.4–123.2 69.6–149.9
NC donors only (n 5 18)
Average 23.7 45.5 69.2
CV (%) 32 23 21
Range 9.0–34.3 30.6–63.8 45.9–87.8
Fig. 6. Individual (blue open circle) and mean (black line) mycophenolic acid
CLint,u,UGT,HKM (ml/min/mg protein) for donors with different allelic variants
for the 2900G . A SNP in the UGT2B7 gene (rs7438135).
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the mean MPPGK obtained here (26.2 mg/g kidney cortex) is in
agreement with the value previously reported for kidney cortex
microsomes (Jakobsson and Cintig, 1973), but it is more than 2-fold
greater than recently reported scalars from unspecified regions or
“mixed” kidney samples (Al-Jahdari et al., 2006; Knights et al., 2016).
Although studies differed in microsomal protein markers used, the
kidney region used is most likely the major contributor to the MPPGK
differences because of higher endoplasmic reticulum content in cortex
relative to medulla. This emphasizes a need for separate MPPGK scalars
for cortex and whole kidney.
In addition to protein marker and kidney region, tissue source and
processing were identified as important factors contributing to variabil-
ity in scalars, as significant differences in MPPGK and CPPGK were
found between the two sources of kidney cortex used in the current
study. Demographic information, such as age, gender, and the medical
history of donors was available for 20 kidney cortex samples from
CMFT Biobank. This data set was insufficient for robust assessment of
any potential demographic covariates ofMPPGK, as reported previously
for MPPGL (Barter et al., 2008). The CMFT Biobank kidney cortex
samples were from donors aged 43 to 83 years at the time of nephrectomy,
which represents a subsection of the overall adult population, a trend
consistent with previous studies (Scotcher et al., 2016b). Further
data are therefore required, particularly for younger subjects, to
investigate any potential relationship between MPPGK/CPPGK and
demographic factors.
The average human CPPGK (53.3 mg/kidney cortex) was approxi-
mately two-thirds of the value reported for CPPGL (Cubitt et al., 2011).
To the authors’ knowledge, the potential contribution of microsomal
GST isoforms within the liver homogenate was not accounted for in
previous studies when GST was used as the cytosolic protein marker for
liver. The estimated human S9 protein per gram of kidney cortex, based
on the combined values of MPPGK and CPPGK, was 79.5 mg/g kidney
cortex (24% CV), which is lower than the corresponding value for liver
(121 mg/g liver), as well as an estimated value of 93.5 mg/g kidney used
previously for scaling ((Nishimuta et al., 2014), calculated from an
MPPGK value of 12.8 mg/g kidney and liver cytosolic recovery of
80.7 mg/g liver).
Impact of Updated MPPGK Scaling Factors on Prediction of Renal
Metabolic Clearance
As the cortex displays predominant UGT expression and greater
blood flow relative to weight than medulla, it is likely that cortex has a
predominant role in renal drug metabolism in vivo. For this reason, the
renal cortex glucuronidation clearance of mycophenolic acid was
estimated by modifying the kidney weight and renal blood flow
parameters accordingly in the well stirred kidney model (Scenario 2)
and compared with predictions based on assumptions of uniform kidney
physiology (Scenario 1). A substantial difference was found between
Scenario 1 and 2 for scaled CLint,u,UGT,HKM, with a less pronounced
difference in the IVIVE of the overall glucuronidation clearance. In the
case of mycophenolic acid, each scenario resulted in adequate prediction
accuracy of its CLUGT (Fig. 7B); however, scenarios differed in their esti-
mated contribution of kidney glucuronidation relative to liver. These differ-
ences highlight the importance of knowing the source (cortex/medulla/
mixed) of microsomes being used for in vitro assays and applying the
correct MPPGK scalar for IVIVE of renal drug metabolism data,
namely, 11.1 mg/g of kidney for mixed kidney and 26.2 mg/g of kidney
for the cortex. In addition, the source of microsomes used would limit
which of the available kidney models are appropriate for prediction of
in vivo metabolic clearance (Fig. 1). Conversely, in vitro data required
to inform parameters of a specific kidney model should be generated using
microsomes prepared from the appropriate region of kidney (Fig. 1).
Mycophenolic acid is an immunosuppressant for which therapeutic
drug monitoring has been proposed owing to a narrow therapeutic
Fig. 7. IVIVE of mycophenolic acid clearance under two different scenarios.
MPPGK, kidney weight, and blood flow parameters used for scaling and in the well
stirred kidney model represented either the whole kidney (Scenario 1) or kidney
cortex (Scenario 2); details are listed in Table 5. (A) Kidney: liver ratios of scaled
mycophenolic acid CLint,u,UGT (ml/min/g tissue). Bars represent mean values; error
bars represent the standard deviation. (B) Prediction accuracy of mycophenolic acid
CLUGT, considering either the hepatic glucuronidation alone or the sum of the hepatic and
renal glucuronidation clearances. The contribution of renal glucuronidation was predicted
using two scenarios. Individual (blue open circle) and mean (black line) data are
shown (n = 20). Solid horizontal line represents line of unity.
TABLE 5
Comparison of scaled mycophenolic acid CLint,u,UGT,HKM and predicted CLUGT in
scenarios that take different assumptions for physiologic parameters (see
Table 2)
Mean values from 20 individual human kidney cortex microsomes are shown, with CVs in
parentheses. Data for individual donors are listed (Supplemental Table S3).
Scenario 1 Scenario 2
CLint,u,UGT,HKM (ml/min/mg protein) 1061 (43%)
MPPGK (mg/g kidney) 11.1a 28.4 (21%)b
Scaled CLint,u,UGT,HKM (ml/min/g kidney) 11.8 (43%) 30.2 (53%)
Kidney:liver ratio for scaled CLint,u,UGT
c 1.26 (43%) 3.24 (53%)
Kidney weight (g/kg body weight) 4.5 3.1
fu,p 0.01 0.01
RB 0.6 0.6
QR (ml/min/kg) 16.4 13.2
Predicted CLR,met,UGT (ml/min/kg) 0.83 (41%) 1.35 (47%)
Kidney: liver ratio for predicted CLmet,UGT 0.29 (41%) 0.47 (47%)
Predicted CLUGT (mL/min/kg)
d 3.70 (9%) 4.21 (15%)
Mean predicted/observed CLUGT
e 0.93 (9%) 1.06 (15%)
a11.1 mg/g kidney used for all donors, calculated as weighted (by donor number) mean of
values recently reported for mixed kidney and unspecified kidney region (Al-Jahdari et al., 2006;
Knights et al., 2016).
bDonor-specific MPPGK values measured in the current study used.
cCLint,u,UGT,HLM was 9.32 ml/min/g liver, which is based on in vitro measurements in the
presence of BSA (Gill et al., 2012).
dCLh,met,UGT (2.86 ml/min/kg) calculated per Gill et al. (2012).
eObserved CLUGT was 3.97 ml/min/kg (Gill et al., 2012).
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window and pronounced interindividual variability in its pharmacoki-
netics and side effects (Dong et al., 2014). Variability of approximately
50% in its CLint,u,UGT,HKM observed in the current study is consistent
with the interindividual variability of clearance reported clinically.
Several factors have been identified as covariates of mycophenolic acid
pharmacokinetics in vivo, including SNPs in UGT1A9 (e.g., 2440T .
C) and 2B7 (e.g.,2900G.A) (Picard et al., 2005; Fukuda et al., 2012).
Of the SNPs investigated in the current study, the UGT2B72900G.A
was the only one linked with variability in mycophenolic acid in vitro
CLint,u,UGT,HKM. This polymorphism occurs in a putative activating
protein 1 binding site in the UGT2B7 promotor and could therefore
affect the activity of the promotor (Hu et al., 2014a), contributing to
interindividual variability in mycophenolic acid renal glucuronidation
observed in vitro.
In conclusion, MPPGK in dogs was characterized for the first
time, in addition to microsomal recoveries obtained for the liver and
intestinal samples from the same animals. MPPGK estimated from
frozen dog samples was lower than MPPGL, but it was greater than
MPPGI, with no direct correlations between scaling factors. Human
MPPGK in kidney cortex, measured in 38 donors (mean: 26.2 mg/g
kidney cortex; range: 9.0–42.6 mg/g kidney cortex) was on average
2-fold higher than the literature MPPGK value commonly used for
IVIVE scaling of renal metabolism data. Human CPPGK was
measured for the first time, with mean and range of 53.3 and
30.6–123.2 mg/g kidney cortex, respectively. The current study
indicates that microsomal and cytosolic scaling factors need to
correspond to the tissue source (i.e., mixed kidney or cortex) used to
prepare the subcellular fractions for in vitro assays. Therefore,
commercial providers of human kidney microsomes and cytosols are
expected to explicitly state the tissue region used. In addition to
using the MPPGK for cortex, the IVIVE of in vitro data obtained in
cortex microsomes needs to account for differences in cortex weight
and blood flow relative to the whole kidney. Mycophenolic acid case
study highlighted the implications of refined scaling factors and
appreciation of regional differences on the prediction of renal
metabolism and its contribution to overall clearance.
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